CELL INTELLIGENCE · 肿瘤细胞治疗研究

多能干细胞来源的 CAR-NK 祖细胞疗法靶向微小残留病并预防白血病模型中的复发

Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models.

供者来源 CD19 靶向 CAR-NK 细胞在 blinatumomab 和自体 CD19 靶向 CAR-T 治疗失败后诱导复发 B-ALL 患儿完全缓解

Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-ta

基于 CircRNA 的 CD19 靶向 CAR-NK 疗法用于 B 细胞急性淋巴细胞白血病，采用粗球孢子菌来源的 II 组内含子平台

CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform.

克服 CAR-T 与 CAR-NK 细胞疗法中的耐药与复发：从实验室到临床

Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.

作者更正：4-1BB 共刺激 CD19 特异性 CAR-NK 细胞疗法治疗复发/难治性大 B 细胞淋巴瘤的安全性与可行性：I 期试验

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a pha

IL-15 与 CCL21 共表达增强 CAR-NK 细胞协同 T 细胞清除肿瘤的能力并赋予其 PI3K/AKT/mTOR 信号特征

Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signat

我们的研究突出了 15 21 CAR-NK 细胞的内在优势及外在 T 细胞协同获益，为基于 NK 细胞的免疫疗法提供了一种有前景的策略。

4-1BB 共刺激 CD19 特异性 CAR-NK 细胞治疗难治/复发性大 B 细胞淋巴瘤的安全性与可行性：一项 1 期试验

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

白细胞介素-21 工程化经富集的代谢通路增强 CD19 特异性 CAR-NK 细胞抗 B 细胞淋巴瘤活性

Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways.

组成型 RLI 装甲增强 CAR-NK 细胞效应功能但导致体内致死性毒性

Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo.

在多拷贝 rDNA 位点定点整合 CAR19 和 IL24 的 iPSC 来源 NK 细胞增强抗肿瘤活性和增殖

iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.